D. Hellenbrecht
Goethe University Frankfurt
6 Papers
74 Citations
D. Hellenbrecht is an academic researcher from Goethe University Frankfurt. The author has contributed to research in topics: Cirrhosis & Metoclopramide. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Metoclopramide kinetics at high‐dose infusion rates for prevention of cisplatin‐induced emesis
R. Saller,D. Hellenbrecht,L Briemann,A. Hellstern,H. Hess,P. Mitrou,M Hodgson,G. Achtert,P. Brockmann,H J Hausleiter +9 more
TL;DR: It appears that metoclopramide kinetics at high doses were dose linear, i.e., without evidence of cumulation, and vomiting was effectively suppressed by both regimens.
23
Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers.
TL;DR: Apart from increased levels of the unchanged drug due to porto-systemic shunt and/or disease-dependent lower glucuronidation rate, the pharmacokinetics of lormetazepam were not altered in cirrhotic patients and it can be concluded that for this group of patients the drug can be administered according to the same dose regimen as that used for normal subjects.
17
•Journal Article
Minimal biliary excretion and enterohepatic recirculation of lormetazepam in man as investigated by a new nasobiliary drainage technique.
TL;DR: Only negligible amounts of lormetazepam are excreted in bile, and the demethylated metabolite lorazepAM was not detectable in the biological samples investigated.
14
Improved benefit/risk ratio of higher-dose metoclopramide therapy during cisplatin-induced emesis.
TL;DR: The results suggest increasing benefit of metoclopramide treatment with increasing doses of the drug, giving from 40% to 95% protection against emesis in patients with cisplatin-induced emesis.
12
•Journal Article
Absolute bioavailability of metoclopramide given orally or by enema in patients with normal liver function or with cirrhosis of the liver.
A Hellstern,D. Hellenbrecht,R. Saller,M. Gatzen,B Manus,G. Achtert,P. Brockmann,H J Hausleiter,U Leuschner +8 more
TL;DR: It can be concluded from this study, that dosage adjustments may be necessary in oral treatment of patients with cirrhosis of the liver, especially if prolonged therapy is required.
9